Baystreet Staff - Tuesday, October 27, 2026 Oncolytics Biotech Inc 10:45 AM EST - Oncolytics Biotech Inc : Announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later squamous cell anal cancer. Oncolytics Biotech Inc shares N.ONCY are trading off one cent at $0.46. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=8962715325597830
